Status:
COMPLETED
Reversal of Remimazolam by a Single Dose of Flumazenil
Lead Sponsor:
Konkuk University Medical Center
Conditions:
Flumazenil Adverse Reaction
Ambulatory Surgery
Eligibility:
FEMALE
20+ years
Phase:
NA
Brief Summary
Remimazolam, a brand-new sedative which has benzodiazepine property. It is an ultra-short acting sedative and regarded as a proper drug for procedural sedation.
Detailed Description
As ambulatory surgery has been increased last two decades, 'Enhanced Recovery After Surgery (ERAS)' also has become an important issue in clinical fields. It is very critical that managing postoperat...
Eligibility Criteria
Inclusion
- participants aged over 20 years scheduled for ambulatory gynecologic surgery.
Exclusion
- allergy or hypersensitivity to flumazenil, benzodiazepines, NSAIDs, 5-HT3
- arrhythmia, myocardial infarction, coronary artery disease
- obstructive sleep apnea
- severe or acute respiratory distress
- tricyclic anti-depressant
- lactose intolerance
- BMI over 30kg/m2
- ASA classification 4 or 5
Key Trial Info
Start Date :
August 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2023
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT05382806
Start Date
August 2 2022
End Date
May 13 2023
Last Update
May 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Konkuk University Medical Center
Seoul, Seoul-T'ǔkpyǒlshi, South Korea, 05030